Literature DB >> 23851507

RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma.

F Yu1, W Gao2, T Yokochi3, Y Suenaga3, K Ando3, M Ohira4, Y Nakamura3, A Nakagawara5.   

Abstract

RUNX3, a runt-related transcription factor, has a crucial role in dorsal root ganglion neurogenesis. Recent studies have suggested that RUNX3 acts as a tumor suppressor in stomach, colon and breast cancer. However, the biological role of RUNX3 in neuroblastoma remains elusive. Here we report that high levels of RUNX3 expression contribute to the favorable outcome in patients with neuroblastoma, whereas low levels of RUNX3 expression result in poor outcome. Array-based analysis suggested that the allelic loss at chromosome 1p36 is one of the reasons why expression of RUNX3 is downregulated in advanced neuroblastomas. Interestingly, the several patients survived from neuroblastoma with both high mRNA expressions of MYCN and RUNX3, suggesting that RUNX3 high expression might overcome the aggressive behavior of MYCN. Exogenous expression of RUNX3 strongly inhibits cell proliferation and migration in neuroblastoma cell lines. Furthermore, RUNX3 reduces the stability of MYCN protein in MYCN-amplified neuroblastoma cell lines, and this RUNX3-mediated MYCN degradation may depend on the physical interaction between RUNX3 and MYCN. Thus, our findings provide a tumor-suppressing mechanism by which RUNX3 inhibits the MYCN activity in neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23851507     DOI: 10.1038/onc.2013.221

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.

Authors:  Karin Melanie Cabanillas Stanchi; Gernot Bruchelt; Rupert Handgretinger; Ursula Holzer
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

2.  MYCN protein stability is a better prognostic indicator in neuroblastoma.

Authors:  Yi Yang; Jie Zhao; Yingwen Zhang; Tianyue Feng; Bo Yv; Jing Wang; Yijin Gao; Minzhi Yin; Jingyan Tang; Yanxin Li
Journal:  BMC Pediatr       Date:  2022-07-11       Impact factor: 2.567

3.  NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.

Authors:  Yusuke Suenaga; S M Rafiqul Islam; Jennifer Alagu; Yoshiki Kaneko; Mamoru Kato; Yukichi Tanaka; Hidetada Kawana; Shamim Hossain; Daisuke Matsumoto; Mami Yamamoto; Wataru Shoji; Makiko Itami; Tatsuhiro Shibata; Yohko Nakamura; Miki Ohira; Seiki Haraguchi; Atsushi Takatori; Akira Nakagawara
Journal:  PLoS Genet       Date:  2014-01-02       Impact factor: 5.917

4.  An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.

Authors:  Zsuzsanna Nagy; Janith A Seneviratne; Maxwell Kanikevich; William Chang; Chelsea Mayoh; Pooja Venkat; Yanhua Du; Cizhong Jiang; Alice Salib; Jessica Koach; Daniel R Carter; Rituparna Mittra; Tao Liu; Michael W Parker; Belamy B Cheung; Glenn M Marshall
Journal:  Nat Commun       Date:  2021-03-25       Impact factor: 14.919

5.  Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma.

Authors:  Jian-Guo Zhou; Bo Liang; Su-Han Jin; Hui-Ling Liao; Guo-Bo Du; Long Cheng; Hu Ma; Udo S Gaipl
Journal:  Front Oncol       Date:  2019-12-04       Impact factor: 6.244

6.  Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma.

Authors:  Jesus García-López; Kirby Wallace; Joel H Otero; Rachelle Olsen; Yong-Dong Wang; David Finkelstein; Brian L Gudenas; Jerold E Rehg; Paul Northcott; Andrew M Davidoff; Kevin W Freeman
Journal:  Cell Rep       Date:  2020-01-14       Impact factor: 9.995

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.